• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Injectable Antibodies. Products, Markets, Players and Forecasts - Product Image

Injectable Antibodies. Products, Markets, Players and Forecasts

  • Published: May 2012
  • Region: Global
  • Greystone Associates

The administration of therapeutic antibodies via injection is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. The inherent instability of protein drugs has led to a number of challenges as the developers of injectable antibodies attempt to deal with packaging, handling, reconstitution and drug administration issues. These challenges are being compounded by the trend to patient self-medication, as population demographics and efforts by managed care providers to control healthcare costs drive the growth in drug self-administration, particularly for chronic conditions. This trend is introducing a new class of naïve users to parenteral drug delivery.

This report analyzes twenty-six injectable/Infusible therapeutic antibody drugs and examines key packaging, dosing, regulatory, economic and competitive factors that represent opportunities, risk factors and potential barriers to commercial success.


- Provides detailed analysis of injectable antibody market segments, market dynamics and market demographics

- Analyzes products, READ MORE >

Executive Summary

Antibody Therapeutics Market Dynamics

The Antibody Therapeutics Marketspace
Clinical Trials and Drug Approvals
The Competitive Landscape
Demographics, Managed Care and Growth
Risks and Opportunities

Formulating Antibody Drugs

Formulation Strategies
Antibody Formulation Technologies
Antibody Packaging & Delivery
Antibody Drug Distribution Strategies

Injectable Antibodies – Indications and Therapeutic Markets

Infectious Disease
Macular Degeneration

Injectable Antibody Drug Product Assessments and Forecasts

Adalimumab (Humira)
Alefacept (Amevive)
Alemtuzumab (Campath)
Belimumab (Benlysta)
Bevacizumab (Avastin)
Brentuximab vedotin (Adcetris)
Canakinumab (Ilaris)
Certolizumab (Cimzia)
Cetuximab (Erbitux)
Denosumab (Prolia)
Eculizumab (Soliris)
Gemtuzumab (Mylotarg)
Golimumab (Simponi)
Ibritumomab (Zevalin)
Infliximab (Remicade)
Natalizumab (Tysabri)
Ofatumumab (Arzerra)
Palivizumab (Synagis)
Panitumumab (Vectibix)
Omalizumab (Zolair)
Ranibizumab (Lucentis)
Rituximab (Rituxin)
Tocilizumab (Actemra)
Tositumomab (Bexxar)
Trastuzumab (Herceptin)
Ustekinumab (Stelara)

Market Factors

Regulatory Issues
Patient Compliance
Healthcare Economics

Company Profiles

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos